Epigenome editing company Tune Therapeutics has announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. Tune Co-Founder Dr Charles Gersbach, whose research at Duke University formed the basis for Tune’s TEMPO epi-editing platform, commented: “Tune has already achieved a global landmark in the field, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!